Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Skin Cancer01:30

Skin Cancer

4.2K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.2K
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

2.0K
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial.

Dermatology and therapy·2026
Same author

Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.

Dermatology and therapy·2026
Same author

Disease Burden in a Cohort of Canadian Adults With Moderate-to-Severe Atopic Dermatitis by Systemic Therapy Use.

Journal of cutaneous medicine and surgery·2026
Same author

Role of scratches and mat hygiene in wrestling-associated skin infections.

JAAD international·2026
Same author

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).

American journal of clinical dermatology·2026
Same author

Recognition of child maltreatment: lessons from history.

Archives of disease in childhood·2025
Same journal

Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study.

Dermatology and therapy·2026
Same journal

Pediatric Psoriasis: Comorbidities, Treatment Challenges and Unmet Needs.

Dermatology and therapy·2026
Same journal

Comparative Data on Long-Term Efficacy of Biologics in Moderate-to-Severe AD: An Expert Perspective on Using Indirect Comparison Methodology.

Dermatology and therapy·2026
Same journal

Comparative Effectiveness and Safety of Baricitinib and Ritlecitinib in Severe Alopecia Areata: A Real-World Monocentric Retrospective Study.

Dermatology and therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Risankizumab Versus Icotrokinra in Adult Patients with Moderate-to-Severe Plaque Psoriasis.

Dermatology and therapy·2026
Same journal

Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival.

Dermatology and therapy·2026
See all related articles

Related Experiment Video

Updated: Jul 13, 2025

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
03:47

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application

Published on: September 27, 2024

915

Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.

Stephen Schleicher1, Angela Moore2,3, Elyse Rafal4

  • 1DermDox Centers for Dermatology, Sugarloaf, PA, USA.

Dermatology and Therapy
|October 15, 2023
PubMed
Summary
This summary is machine-generated.

Trifarotene significantly reduced atrophic acne scars and lesions in a 24-week study. This topical retinoid demonstrated effectiveness and good tolerability for moderate-to-severe acne vulgaris and associated scarring.

Keywords:
Acne vulgarisAtrophic scarClinical studyTrifarotene

More Related Videos

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

940
Author Spotlight: Development and Evaluation of a Compound Acne Rodent Model Using C. acnes and Oleic Acid
03:10

Author Spotlight: Development and Evaluation of a Compound Acne Rodent Model Using C. acnes and Oleic Acid

Published on: November 1, 2024

2.6K

Related Experiment Videos

Last Updated: Jul 13, 2025

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
03:47

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application

Published on: September 27, 2024

915
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

940
Author Spotlight: Development and Evaluation of a Compound Acne Rodent Model Using C. acnes and Oleic Acid
03:10

Author Spotlight: Development and Evaluation of a Compound Acne Rodent Model Using C. acnes and Oleic Acid

Published on: November 1, 2024

2.6K

Area of Science:

  • Dermatology
  • Cutaneous Medicine
  • Acne Research

Background:

  • Atrophic acne scarring is a common sequela of acne vulgaris.
  • Topical retinoids are established treatments for acne, but their efficacy for atrophic scars is less documented.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of trifarotene for treating moderate-to-severe facial acne and atrophic acne scars.

Main Methods:

  • A 24-week, randomized, split-face, double-blind study involving 121 participants (ages 17-34) with moderate-to-severe facial acne and scars.
  • Participants applied either trifarotene 50 μg/g or vehicle once daily.
  • Efficacy was measured by changes in atrophic scar counts, Scar Global Assessment (SGA), Investigator's Global Assessment (IGA) success rates, and acne lesion counts.

Main Results:

  • Trifarotene showed a statistically significant greater reduction in atrophic scar count compared to vehicle by week 24 (-5.9 vs -2.7, p<0.0001).
  • Higher SGA success rates were observed with trifarotene at week 12 (14.9% vs 5.0%) and week 24 (31.3% vs 8.1%).
  • Trifarotene also led to significantly higher IGA success rates (63.6% vs 31.3%) and greater reductions in total and inflammatory acne lesions.

Conclusions:

  • Trifarotene is effective and well-tolerated for treating moderate-to-severe facial acne and reducing atrophic acne scars.
  • Scar count reduction was observed as early as week 2 of treatment.